SCHEMBL4420290

SCHEMBL4420290

CCOC(=O)c1cc(C(C)(C)C)c(N)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.46
KDM4E B2RXH2 7/20 0.46
HPGD P15428 6/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HSD17B10 Q99714 1/20 0.46
MMP13 P45452 4/20 0.45
MMP2 P08253 3/20 0.45
LMNA P02545 4/20 0.44
MAPT P10636 4/20 0.44
NPC1 O15118 3/20 0.44
KMT2A Q03164 3/20 0.44
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
GLA P06280 1/20 0.44
ATM Q13315 1/20 0.44
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HTT P42858 2/20 0.43
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199077 0.79 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL22455541 0.74 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL13330085 0.73 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL10003980 0.73 KDM4E (0.52) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL10003164 0.73 KDM4E (0.47) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL3061979 0.72 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10LMNAMAPT
SCHEMBL6302965 0.72 KDM4E (0.58) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL17647705 0.71 CYP1A2 (0.46) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL3736476 0.71 GABRP (0.47) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL12277699 0.71 KDM4E (0.57) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606255-B1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2009-11-11 EP disclosed
EP-1656138-A4 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-04-18 EP disclosed
EP-1606255-A4 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-02-07 EP disclosed
EP-1656138-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
EP-1656345-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
EP-1606255-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2005-12-21 EP disclosed
WO-2005020899-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed
WO-2005021500-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed
WO-2004071460-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-26 WO disclosed